Target Search | CytoTargetDB

Only direct cytotoxic targets are shown

Gene

Drug Category

Drug Class

Binding Type

antigen recognition (3404)

other (145)

receptor ligand recognition (192)

Annotation Status

ai (3167)

manual_review_required (574)

Disease Type

CANCER (2959)

NON-CANCER (780)

Tissue

OncoTree Main Type

OncoTree Name

Items per page

Download CSV

Gene	NCT ID	Antigen/Ligand	Binding Type	Drug Name	Drug Category	Drug Class	Drug Description	Drug Mechanism of Action	Target Cytotoxicity Mechanism	Disease	Disease Type	Tissue	OncoTree Main Type	OncoTree Name	Annotation Status
CD7	NCT06674382	CD7	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Inhibitor	Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.	Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.	ATG antibodies bind CD7 on T cells and induce complement-dependent lysis and Fc-mediated ADCC/opsonophagocytic clearance, depleting CD7+ cells.	Myelofibrosis	CANCER	Myeloid	Myeloproliferative Neoplasms	Primary Myelofibrosis	manual_review_required
CD8A	NCT06674382	CD8 (alpha chain)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Inhibitor	Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.	Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.	ATG antibodies bind CD8α on T cells and trigger complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance, depleting CD8+ cells.	Myelofibrosis	CANCER	Myeloid	Myeloproliferative Neoplasms	Primary Myelofibrosis	manual_review_required
ITGAL	NCT06674382	CD11a (LFA-1 alpha)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Inhibitor	Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.	Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.	ATG contains antibodies that bind CD11a on T cells, leading to complement-dependent lysis and Fc-mediated ADCC/phagocytic clearance of the bound cells.	Myelofibrosis	CANCER	Myeloid	Myeloproliferative Neoplasms	Primary Myelofibrosis	manual_review_required
ITGB2	NCT06674382	CD18 (LFA-1 beta)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Inhibitor	Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.	Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.	ATG contains polyclonal antibodies that bind T-cell surface antigens including LFA-1 (CD18), leading to complement-dependent lysis, Fc-mediated ADCC, and phagocytic clearance of the bound cells.	Myelofibrosis	CANCER	Myeloid	Myeloproliferative Neoplasms	Primary Myelofibrosis	manual_review_required
IL2RA	NCT06674382	CD25 (IL-2 receptor alpha)	antigen recognition	Anti-thymocyte globulin (ATG)	CYTOTOXIC ANTIBODY	Inhibitor	Polyclonal antibody preparation that depletes T cells to reduce graft rejection and GVHD.	Polyclonal anti–T-cell immunoglobulins that bind multiple T-cell surface antigens and deplete T cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and phagocytic clearance, producing immunosuppression to prevent graft rejection and GVHD.	Polyclonal ATG antibodies bind T-cell antigens (including CD25) and eliminate bound CD25+ cells via complement-dependent lysis, antibody-dependent cellular cytotoxicity, and opsonization/phagocytic clearance.	Myelofibrosis	CANCER	Myeloid	Myeloproliferative Neoplasms	Primary Myelofibrosis	manual_review_required